Is MSTR a buy, hold, or sell?
MSTR carries a valuation grade of Strong Buy. Our discounted cash flow model produces an intrinsic range of $118–$394 — implying a +122% margin of safety at the current price of $115.35. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 3% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter missed by a 149.6% earnings surprise. Analyst estimate revisions are trending downward.
What are MSTR's key risk factors?
With a beta of 3.47, MSTR exhibits a highly aggressive risk profile relative to the broad market. The 95th-percentile CVaR of -47.6% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 4.8% of total portfolio loss in the worst 5% of months. The balance sheet is conservatively leveraged at 18% debt-to-equity.
Implied volatility of 3.0% is below realized volatility of 70.6%, potentially making options relatively cheap. Insiders have been net sellers to the tune of $149.9M recently. While routine dispositions are common, the magnitude bears watching. Short interest of 11.4% of float is elevated, reflecting meaningful bearish positioning.
How does MSTR fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — MSTR carries a beta of 3.47, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, MSTR shows the strongest co-movement with COIN (0.74), HOOD (0.61), NVDA (0.37). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios. With the top peer correlation at 0.74, adding MSTR to a portfolio that already holds these names provides limited marginal diversification benefit — particularly during stress events when correlations converge toward 1.0.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The MSTR analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning MSTR’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
